Explore the words cloud of the SYST-iMYC project. It provides you a very rough idea of what is the project "SYST-iMYC" about.
The following table provides information about the project.
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
|Coordinator Country||Spain [ES]|
|Total cost||148˙875 €|
|EC max contribution||148˙875 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2018-07-01 to 2019-12-31|
Take a look of project's partnership.
|1||FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON||ES (BARCELONA)||coordinator||148˙875.00|
Current cancer therapies target redundant cellular functions often compensated for by cancer cells, resulting in resistance to treatment. Here we propose an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target for human cancer. Targeting Myc has long been considered unfeasible because of the potentially catastrophic side effects in normal tissues. Against this dogma, we showed that Myc inhibition by Omomyc, a Myc mutant designed by Dr. Soucek, has a dramatic therapeutic impact in multiple mouse models of cancer, while causing only limited and reversible side effects. Critically, there is no emergence of resistance. Thanks to the ERC-2013-CoG n° 617473, we discovered the unexpected cell-penetrating properties of the purified Omomyc polypeptide. Moreover, we found that it is anti-tumorigenic after local (intranasal) delivery to mouse models of lung and brain tumors, and could therefore become the first clinically-viable direct Myc inhibitor. With this ERC PoC, we propose to develop a new drug based on an Omomyc variant that enables systemic treatment of several cancer types including lymphoma, breast, and melanoma. In all these cancers Myc contributes to multiple aspects of tumorigenesis including immune suppression. At the end of this project we will have a patent protected therapeutic polypeptide active in vitro and in vivo and ready to enter clinical trials Phase I/II in patients and to continue its commercialization. The forecasted peak revenue for such first-in-class drug in those indications reaches 2.612 M€ annually. With this ERC PoC project we will achieve essential milestones to develop this innovative therapeutic polypeptide by establishing the feasibility, including a commercial data package and cost estimations for the industrial production. Passing these milestones will de-risk the product and increase its value and probability of reaching the market by making it ready to be transferred to a spin-off company.
|year||authors and title||journal||last update|
Mireia Pesarrodona, Toni Jauset, Zamira V. DÃazâ€Riascos, Alejandro SÃ¡nchezâ€Chardi, Marieâ€Eve Beaulieu, Joaquin Serasâ€Franzoso, Laura SÃ¡nchezâ€GarcÃa, Ricardo BaltÃ â€Foix, Sandra Mancilla, Yolanda FernÃ¡ndez, Ursula Rinas, SimÃ³ Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther VÃ¡zquez
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies
published pages: 1900849, ISSN: 2198-3844, DOI: 10.1002/advs.201900849
|Advanced Science 6/18||2020-03-05|
S. RamÃ³n y Cajal, P. Sancho, L. Soucek, H. Peinado, M. Abad, M. Valiente, A. Efeyan, J. Pardo, V. Quesada, J. Jimeno, P. M. Duque, A. AntÃ³n, I. Varela, A. J. Schuhmacher
A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas
published pages: , ISSN: 1699-048X, DOI: 10.1007/s12094-019-02199-4
|Clinical and Translational Oncology||2020-02-28|
SÃlvia Casacuberta-Serra, Laura Soucek
Myc and Ras, the Bonnie and Clyde of immune evasion
published pages: S457-S459, ISSN: 2218-676X, DOI: 10.21037/tcr.2018.03.09
|Translational Cancer Research 7/S4||2020-02-28|
Marie-Eve Beaulieu, Toni Jauset, Daniel MassÃ³-VallÃ©s, Sandra MartÃnez-MartÃn, Peter Rahl, LoÃ¯ka Maltais, Mariano F. Zacarias-Fluck, SÃlvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Meritxell SÃ¡nchez-HervÃ¡s, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, GÃ©nesis MartÃn, Danny Letourneau, Martin Montagne, Migu
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
published pages: eaar5012, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aar5012
|Science Translational Medicine 11/484||2020-02-28|
Jonathan Whitfield, Laura Soucek
Editorial overview: Peptides in cancer
published pages: iii-v, ISSN: 1471-4892, DOI: 10.1016/j.coph.2019.06.001
|Current Opinion in Pharmacology 47||2020-02-28|
Marie-Eve Beaulieu, Laura Soucek
published pages: e1618178, ISSN: 2372-3556, DOI: 10.1080/23723556.2019.1618178
|Molecular & Cellular Oncology 6/5||2020-02-28|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYST-IMYC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SYST-IMYC" are provided by the European Opendata Portal: CORDIS opendata.